

# Eileen E Parkes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6154589/publications.pdf>

Version: 2024-02-01

26  
papers

1,035  
citations

687220

13  
h-index

713332

21  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1989  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw199.   | 3.0 | 338       |
| 2  | Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. <i>Cancer Discovery</i> , 2021, 11, 1212-1227.   | 7.7 | 139       |
| 3  | Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.   | 7.7 | 130       |
| 4  | Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application. <i>Briefings in Bioinformatics</i> , 2019, 20, 1795-1811. | 3.2 | 112       |
| 5  | Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. <i>British Journal of Cancer</i> , 2020, 123, 1089-1100.                            | 2.9 | 51        |
| 6  | Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. <i>Journal of Oncology</i> , 2018, 2018, 1-14.                                | 0.6 | 44        |
| 7  | Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3484-3492.                                 | 0.8 | 30        |
| 8  | A BRCA1 deficient, NF $\kappa$ B driven immune signal predicts good outcome in triple negative breast cancer. <i>Oncotarget</i> , 2016, 7, 19884-19896.   | 0.8 | 30        |
| 9  | When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers. <i>Trends in Cancer</i> , 2022, 8, 174-189.  | 3.8 | 27        |
| 10 | Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer. <i>Oncologist</i> , 2016, 21, 586-593.  | 1.9 | 23        |
| 11 | The clinical and molecular significance associated with STING signaling in breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 81.   | 2.3 | 21        |
| 12 | DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. <i>Journal of Oncology</i> , 2019, 2019, 1-14.   | 0.6 | 18        |
| 13 | Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. <i>Gut</i> , 2019, 68, 1918-1927.   | 6.1 | 18        |
| 14 | Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study. <i>Cancer Causes and Control</i> , 2020, 31, 1-11.  | 0.8 | 16        |
| 15 | Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 247-258.  | 2.9 | 14        |
| 16 | Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. <i>British Journal of Cancer</i> , 2021, 124, 581-586.                | 2.9 | 9         |
| 17 | Clinical Tumor Staging of Adenocarcinoma of the Esophagus and Esophagogastric Junction. <i>Journal of Clinical Oncology</i> , 2015, 33, 1088-1088.  | 0.8 | 5         |
| 18 | Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors. <i>Cancer Research</i> , 2021, 81, CT217-CT217.       | 0.4 | 5         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Abstract 3787: Exploring the effect of chemotherapies on STING-dependent cytokine release. <i>Cancer Research</i> , 2018, 78, 3787-3787.   | 0.4  | 2         |
| 20 | PD-L1 expression and response to neo-adjuvant chemotherapy in esophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4023-4023.   | 0.8  | 1         |
| 21 | A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3637-TPS3637. | 0.8  | 1         |
| 22 | NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2682-TPS2682.   | 0.8  | 1         |
| 23 | Make it easier for me to deliver childcare at conferences. <i>Nature</i> , 2018, 564, S89-S89.   | 13.7 | 0         |
| 24 | Turning the concept of synthetic lethality on its head. <i>Translational Cancer Research</i> , 2016, 5, S1145-S1148.   | 0.4  | 0         |
| 25 | Exploration of the cGAS-STING pathway in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5075-5075.  | 0.8  | 0         |
| 26 | Consensus gene expression analysis to identify key hallmarks of cancer in malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21045-e21045.  | 0.8  | 0         |